Vivos Therapeutics, Inc. (VVOS) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
The consensus price target is $2.25, representing an upside of 66.7% from the current price $1.35.
Analysts estimate Earnings Per Share (EPS) of $-2.02 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.68 vs est $-2.02 (beat +16.8%). Analyst accuracy: 80%.
VVOS Stock — 12-Month Price Forecast
$2.25
▲ +66.67% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Vivos Therapeutics, Inc., the price target is $2.25.
The average price target represents a +66.67% change from the last price of $1.35.
VVOS Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Vivos Therapeutics, Inc. in the past 3 months
EPS Estimates — VVOS
80%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual –$1.68
vs Est –$2.02
▲ 20.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — VVOS
99%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.015B
vs Est $0.015B
▼ 1.1% off
Revenue Trend
Analysts expect stable revenue going forward.
